Page 146 - 《南京医科大学学报(自然科学版)》2026年第3期
P. 146

第46卷第3期
               ·454 ·                            南 京    医 科 大 学 学         报                        2026年3月



                                            表1 5例DPPX抗体相关脑炎患者的临床特征
                           Table 1 Clinical characteristics of five patients with DPPX antibody⁃associated encephalitis

               Characteristic    Case 1       Case 2            Case 3             Case 4           Case 5
               Age(years)         32            14               33                  17              56
               Sex               Male          Male              Male               Male             Male
               Onset to         10 days       20 days   4 years(diagnosed with viral  10 days      7 months
               diagnosis                                  encephalitis for 4 years)
               Onset mode        Acute        Acute             Acute              Acute           Subacute
               Initial symptoms  Seizure    Psychiatric   Psychiatric disturbances  Headache       Amnesia
                                            disturbances
               Other symptoms   Amnesia      Amnesia,   Fever,amnesia,confusion,  Migrating      Ataxia,seizure,
                                             confusion  seizure, headache, con⁃   myoclonus     confusion,sleep
                                                        sciousness disturbance                     disorder
               MRI              Normal        Normal            Normal             Normal      Increased signal in
                                                                                                bilateral temporal
                                                                                                     lobe
               EEG               Severe       Normal    ①Normal;                   Normal           Normal
                                 diffuse                ②Mild diffuse polymorphic
                              polymorphic               slowing;
                                slowing                 ③Mild diffuse polymorphic
                                                        slowing
                                                                     3
               CSF               WBC          Normal    ① WBC 78/mm ,normal        Normal        Normal WBC,
                                32/mm ,       WBC,      protein;                  WBC and       protein 59 mg/dL
                                     3
                                                                     3
                                 normal       protein   ② WBC 20/mm ,normal        protein
                                 protein     63 mg/dL   protein;
                                                                     3
                                                        ③ WBC 19/mm ,protein
                                                        71.2 mg/dL
               DPPX antibody    CSF(-),      CSF(-),       CSF 1∶1,blood 1∶10     CSF(-),        CSF(-),blood
               titer          blood 1∶100   blood 1∶100                          blood 1∶100         1∶32
               Other antibody    (-)         Anti⁃TPO>    Anti⁃TPO:126.3 U/mL,   Anti⁃CASPR2        (-)
                                             600 U/mL,     anti⁃TG:63.2 U/mL        1∶10
                                              anti⁃TG
                                            345.03 U/mL
               Treatment      IG,MP,AED       IG,MP             IG,MP           IG(twice),MP,   MP(twice),MMF,
                                                                                  CZP,VPA            AED
               Tumor             (-)           (-)              (-)                 (-)             (-)
               mRS
                Initial            3            3                 5                  2                4
                Last follow⁃up     1            2                 2                  1                2
               Follow⁃up period   60            65               108                 40              72
              (months)
                 ①January 6,2016;②March 26,2019;③November 29,2019;CSF:cerebrospinal fluid;EEG:electroencephalography;WBC:white blood cell;
              anti⁃TPO:thyroid peroxidase antibody;anti⁃TG:thyroglobulin antibody;mRS:modified Rankin scale;IG:immunoglobulin;MP:methylprednisolone;
              AED:antiepileptic drugs;CZP:clonazepam;VPA:valproic acid.
              受 MP 治疗,未接受 IG 治疗,复发后患者接受 MP 和
                                                                3 结     论
              MMF治疗。在随访期间,所有患者的改良Rankin评
              分均有改善。                                                 本研究回顾性分析了 5 例 DPPX 抗体相关脑炎
   141   142   143   144   145   146   147   148   149   150   151